These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9122147)

  • 1. [Prevention of opportunistic infections in HIV seropositive patients. Prevention of parasitic infections].
    Casassus P; Padrazzi B; Lhote F; Jarrousse B
    Presse Med; 1997 Mar; 26(7):334-9. PubMed ID: 9122147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
    N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Bucher HC; Griffith L; Guyatt GH; Opravil M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
    Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
    Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
    Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
    Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
    Payen MC; De Wit S; Sommereijns B; Clumeck N
    Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing opportunistic infections.
    Cheng B
    PI Perspect; 1995 May; (no 16):14-5. PubMed ID: 11362422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Secondary prevention of opportunistic infections in HIV-infected patients].
    Asencio Marchante R; Lissen Otero E
    Rev Clin Esp; 2001 Feb; 201(2):88-9. PubMed ID: 11345612
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy and prophylaxis of systemic protozoan infections.
    Van Voorhis WC
    Drugs; 1990 Aug; 40(2):176-202. PubMed ID: 2121456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
    García Vázquez E; de Górgolas Hernández M; García Delgado R; Fernández Guerrero ML
    Med Clin (Barc); 1999 Jun; 113(3):89-90. PubMed ID: 10464742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing PCP therapy.
    Torres G; Cadman J
    GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumocystis carinii pneumonia prophylaxis during pregnancy.
    Connelly RT; Lourwood DL
    Pharmacotherapy; 1994; 14(4):424-9. PubMed ID: 7937279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
    Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
    N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of parasitic infections (excluding toxoplasmosis) in immunocompromised patients].
    Hennequin C
    Ann Med Interne (Paris); 1997; 148(3):240-5. PubMed ID: 9255333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.